Renalytix plc - RNLX Enterprise Value-to-Revenue Multiple

Renalytix plc (RNLX) - corporate logo

Renalytix Plc (RNLX) is developing AI diagnostics for renal pathologies, leveraging the expansion of insurance reimbursements and new contracts. The EV/Sales multiple trajectory, with a value fixed at , demonstrates the current balance of business value to revenue. Success is driven by the synergy between data scientists and medical professionals and strong patent protection of technologies, which creates significant barriers to entry for new players.

RNLX: Renalytix AI EV/Sales Multiple 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Renalytix Plc (RNLX)

- cash and cash flow indicators:
Fundamental valuation:Renalytix, plc (RNLX)
Flagship merchandise of Renalytix, plc

The investor determines the asset's margin of safety through the ratio of enterprise value (EV) to revenue, which allows for an assessment of the company's market price regardless of its debt load. Against a backdrop of slow AI diagnostics adoption and a liquidity shortage at Renalytix Plc (RNLX), the EV/Sales multiple trajectory serves as an indicator of either critical undervaluation or systemic impairment of this high-risk speculative asset.